Company intelligence / Profile preview
Geropharm
Obolensk, Moscow region, Russiageropharm.com ↗
- Ownership
- Private
- Development stage
- Commercial
01
Overview
Geropharm is a Russian biotechnology company that produces insulin on a full-cycle basis. The company recently received authorization for Sejaro, an innovative medicinal product for treating obesity in Russia. They also produce Retinalamin for diabetic retinopathy and Pineamin for menopausal syndrome. Their insulin production can cover 30% of Russian needs, with plans to expand to 100% coverage.
- Therapeutic areas
- OphthalmologyEndocrinologyNeurologyWomen's Health
- Modalities
- Biological productsBiosimilarsSmall molecule drugsSynthetic peptides
- Industry
- Biotech
02
Drug pipeline
16 assets15 more assets in the full pipeline.
Request access →03
Partnerships
Espromed Bio (Venezuela)
Beyond the preview
Go deeper on Geropharm.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Geropharm.